DK2877494T3 - PTPRS og proteoglycaner i autoimmun sygdom - Google Patents

PTPRS og proteoglycaner i autoimmun sygdom Download PDF

Info

Publication number
DK2877494T3
DK2877494T3 DK13823022.2T DK13823022T DK2877494T3 DK 2877494 T3 DK2877494 T3 DK 2877494T3 DK 13823022 T DK13823022 T DK 13823022T DK 2877494 T3 DK2877494 T3 DK 2877494T3
Authority
DK
Denmark
Prior art keywords
ptprs
proteoglycans
autoimmune disease
autoimmune
disease
Prior art date
Application number
DK13823022.2T
Other languages
English (en)
Inventor
Nunzio Bottini
Stephanie Stanford
Original Assignee
La Jolla Inst Allergy & Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Inst Allergy & Immunology filed Critical La Jolla Inst Allergy & Immunology
Application granted granted Critical
Publication of DK2877494T3 publication Critical patent/DK2877494T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048Protein-tyrosine-phosphatase (3.1.3.48)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
DK13823022.2T 2012-07-23 2013-07-23 PTPRS og proteoglycaner i autoimmun sygdom DK2877494T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261674853P 2012-07-23 2012-07-23
US201261675036P 2012-07-24 2012-07-24
US201361832688P 2013-06-07 2013-06-07
PCT/US2013/051723 WO2014018554A1 (en) 2012-07-23 2013-07-23 Ptprs and proteoglycans in autoimmune disease

Publications (1)

Publication Number Publication Date
DK2877494T3 true DK2877494T3 (da) 2020-09-21

Family

ID=49997782

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13823022.2T DK2877494T3 (da) 2012-07-23 2013-07-23 PTPRS og proteoglycaner i autoimmun sygdom

Country Status (5)

Country Link
US (2) US20150175979A1 (da)
EP (1) EP2877494B1 (da)
DK (1) DK2877494T3 (da)
ES (1) ES2817897T3 (da)
WO (1) WO2014018554A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US20190160146A1 (en) * 2016-05-12 2019-05-30 Ohio State Innovation Foundation Peptides and methods for treating neurodegenerative disorders
WO2018176019A1 (en) 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
CN113015746A (zh) * 2018-09-19 2021-06-22 拉荷亚免疫研究所 在类风湿性关节炎中的ptprs和蛋白聚糖
CA3225321A1 (en) * 2021-07-30 2023-02-02 Nunzio Bottini Ptprs in autoimmunity

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖rna仲介遺伝子抑制
WO2007041317A2 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
EP2531859A4 (en) * 2010-02-02 2013-07-31 Jolla Inst Allergy Immunolog COMPOSITIONS AND METHOD FOR MODULATING RECEPTOR PROTEIN TYROSINE PHOSPHATASES
BR112013027631A2 (pt) 2011-04-28 2022-01-04 Sbi Biotech Co Ltd Método para a produção de anticorpo monoclonal ou fragmento que inclui uma região de ligação ao antígeno do mesmo, anticorpo monoclonal ou um fragmento que inclui uma região de 5 ligação ao antígeno do mesmo, hibridoma, método para a detecção de uma célula dendrítica plasmocitóide, uso de um anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, e método ex vivo para suprimir a atividade de uma célula dendrítica plasmocitóide

Also Published As

Publication number Publication date
WO2014018554A1 (en) 2014-01-30
EP2877494B1 (en) 2020-07-15
US20150175979A1 (en) 2015-06-25
EP2877494A1 (en) 2015-06-03
EP2877494A4 (en) 2016-04-20
ES2817897T3 (es) 2021-04-08
US20220325261A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2839860T3 (da) Pyrrolobenzodiazepiner og konjugater deraf
DK3470086T3 (da) Pyrrolobenzodiazepiner og konjugater deraf
DK2850202T3 (da) Fremgangsmåder og grupper
DK2844282T3 (da) Prostata-associerede antigener og vaccine-baserede immunterapiregimener
DK2838596T3 (da) Intermitterende katetersamling
HK1206667A1 (en) Extracellular matrix encasement structures and methods
DK2815483T3 (da) Flerrumsatterioplader
BR302012004119S1 (pt) Configuração aplicada em unidade de carga
BR302013000588S1 (pt) Configuração aplicada em instrumento médico
BR112014000049A2 (pt) pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
BR112012029414A2 (pt) arquiteturas ordenadas em polímeros acrílicos
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
DK2877494T3 (da) PTPRS og proteoglycaner i autoimmun sygdom
BR302013000213S1 (pt) Configuração aplicada em instrumento médico
BR302012006078S1 (pt) Configuração aplicada em instrumento médico
FR3015775B1 (fr) Butee de cosse de batterie et unite de cosse de batterie
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
GB2511282B (en) Improvements in or relating to hinge arrangements
BR112013013208A2 (pt) bogie e sua estrutura lateral
DK2812435T3 (da) Transskriptionsenheder og anvendelse heraf i ekspressionsvektorer
BR302013000215S1 (pt) Configuração aplicada em instrumento médico
BR302012006533S1 (pt) Configuração aplicada em bisnaga
BR302012006534S1 (pt) Configuração aplicada em bisnaga